Financial Results (Unaudited) For Quarter Ended September 30, 2025 Overview Q3 2025 Financial Results - Summary • Revenue for the quarter ended as of 30 September 2025 on a like-for-like basis (excluding sub-scale lower- margin third-party product lines) was $14.2m vs Q3, 2024 $14.6m. • The Company experienced significant quarter-on-quarter increase in revenue in Q3, 2025 following strong UniGold HIV sales combined with the resumption in manufacture and supply of its flagship rapid HIV test, TrinScreen HIV ...

2025Q3 Performance Highlights - Hotel RevPAR was RMB 124, down 84% compared with 2024Q3[14] - Restaurant Average Daily Sales Per Store (ADS) was RMB 3,714, down 241% compared with 2024Q3[14] - Hotel Revenues were RMB 2545 million, down 113% compared with 2024Q3[14] - Hotel Income from Operations was RMB 691 million, down 305% with a margin of 272% compared with 2024Q3[14] - Adjusted Income from Operations was RMB 1093 million, up 36% with a margin of 405% compared with 2024Q3[14] - Net Income was RMB 595 million, up 15% with a margin of 234% compared with 2024Q3[14] - Adjusted Net Income was RMB 905 million, up 57% with a margin of 284% compared with 2024Q3[14] - Adjusted EBITDA was RMB 1150 million, down 61% with a margin of 379% compared with 2024Q3[14] Strategic Execution - Further Expansion into Mid-to-Upscale Segment[43] - Greater Penetration in Tier 3 and Lower Cities in South China[43]

Financial Performance - Revenue for Q2 2025 was $10.8 million, a decrease compared to $15.8 million in Q2 2024[4, 7] - Like-for-like revenue (excluding sub-scale lower-margin third-party product lines) was $10.7 million in Q2 2025, versus $15.0 million in Q2 2024[7] - Gross profit was $4.6 million in Q2 2025, down from $5.7 million in Q2 2024[7] - Gross margin improved to 42.6% in Q2 2025, compared to 36.2% in Q2 2024[7] - Net loss was $6.0 million in Q2 2025, an improvement from $6.8 million in Q2 2024[4] - Basic and diluted loss per ADS was $0.32 in Q2 2025, compared to $0.71 in Q2 2024[4] - Adjusted EBITDA was negative $2.1 million in Q2 2025, compared to negative $1.4 million in Q2 2024[4] Expenses and Liquidity - R&D expense was $0.6 million in Q2 2025, compared to $0.9 million in Q2 2024, with $1.7 million capitalized[10] - SG&A expense was $7.0 million in Q2 2025, up from $6.4 million in Q2 2024, driven by foreign exchange loss and corporate finance activities[10] - Restructuring costs were $0.7 million in Q2 2025, compared to $1.9 million in Q2 2024[10] - Cash balance at the end of Q2 2025 was $1.5 million, down from $5.3 million in Q2 2024[10]

Acquisition Overview - CACI International Inc acquired ARKA Group on December 22, 2025[1] - The acquisition aligns with CACI's disciplined M&A strategy[9] - The transaction is expected to close in Q3 of FY26, subject to regulatory approvals and customary closing conditions[28] Strategic Rationale - ARKA is a leading technology provider to the national security space community[8] - ARKA's technologies are complementary to CACI's in the space domain[8] - The acquisition expands CACI's customer presence within the Intelligence Community (IC) and Department of War (DoW)[8] - The combined entity will be a leading provider of actionable intelligence across all domains[22] Financial Highlights - ARKA has a double-digit revenue growth profile and "low 20%" EBITDA margins[8] - Approximately 90% of ARKA's revenue comes from national security customers[24] - ARKA has a backlog of approximately $600 million[24] - The purchase price is 12.3x ARKA's estimated FY25 EBITDA[28]

Financial Performance Highlights - Achieved a record full year Adjusted Net Income of $3.1 billion[11], significantly outperforming initial guidance due to strong demand and effective cost management[1]. - Adjusted Earnings Per Share (Diluted) reached $2.25, exceeding the December guidance by approximately $0.55[13]. - Adjusted EBITDA for the full year reached $7.2 billion, surpassing the December guidance by approximately $600 million[13]. - Adjusted ROIC exceeded 13%, the highest in nearly 20 years[11]. - Reduced total debt by over $10 billion since early 2023[45]. Q4 2025 Performance - Q4 2025 Adjusted Net Income was $0.45 billion, nearly 2.5 times the levels of Q4 2024[12]. - Q4 2025 Adjusted EBITDA reached $1.48 billion, exceeding guidance of $1.34 billion[12]. - Net yields outperformed guidance by 110 basis points, reaching 5.4% compared to the guided 4.3%[12]. 2026 Outlook - The company projects Net Debt to Adjusted EBITDA ratio of under 3.0x for 2026, inclusive of over $0.8 billion of dividend payments[49]. - Expects Adjusted Net Income of approximately $3.45 billion and Adjusted Earnings Per Share (Diluted) of $2.48 for FY 2026[14]. - Anticipates Adjusted EBITDA of approximately $7.63 billion for FY 2026[14]. Strategic Initiatives - Reinstated dividend payments at an initial rate of $0.15 per share[1]. - Successfully completed a refinancing plan, refinancing $19 billion of debt in 2025[45]. - Simplified capital structure and optimized future debt maturities[46].

Financial Performance - Net revenues increased by 12.3% to $702.7 million in F26 Q1 compared to $625.6 million in F25 Q1[34, 35] - Gross margin increased by 40 bps to 12.7% in F26 Q1 from 12.3% in F25 Q1[34, 35] - Operating income increased to $13.8 million in F26 Q1, compared to an operating loss of $(0.9) million in F25 Q1[34, 35] - Adjusted diluted earnings per share increased to $0.38 in F26 Q1, compared to $(0.03) in F25 Q1[34, 35] Segment Results - Towable RV segment net revenues increased by 15.5% to $293.4 million in F26 Q1 compared to $254.0 million in F25 Q1[37, 38] - Motorhome RV segment net revenues increased by 13.5% to $308.5 million in F26 Q1 compared to $271.7 million in F25 Q1[44, 45] - Marine segment net revenues increased by 2.2% to $92.5 million in F26 Q1 compared to $90.5 million in F25 Q1[51, 52] Market Trends and Outlook - The company expects CY2025 wholesale RV shipments to be between 335,000 and 345,000 units[18] - The company expects CY2026 wholesale RV shipments to be between 315,000 and 345,000 units[18] - Barletta's market share in the U S aluminum pontoon segment reached 9.1% in F26, with an October monthly share of 12.8%[20] Fiscal 2026 Guidance - The company estimates net revenues between $2.8 billion and $3.0 billion for FY26, representing a potential 4% increase at the midpoint compared to $2.80 billion in FY25[65] - The company estimates adjusted earnings per share between $2.10 and $2.80 for FY26, representing a potential 47% increase at the midpoint compared to $1.67 in FY25[65]

Transaction Overview - Volaris and Viva shareholders will combine their holding companies into Volaris' holding company through a merger of equals[15] - Equity holders in Viva will receive newly issued shares of Volaris, and each side will own 50% of the combined holding company on a fully diluted basis[15] - The transaction is expected to close in 2026, subject to shareholders' vote and applicable regulatory approvals[15] Combined Company Strength - The combined company will have a broad network with 86 destinations, 324 routes, and 991 daily flights[20] - As of 3Q'25, Volaris had 225 routes (128 domestic and 97 international) and Viva had 184 routes (140 domestic and 44 international)[16] - As of 3Q'25, Volaris transported 306 million passengers (226 million domestic and 80 million international) and Viva transported 296 million passengers (263 million domestic and 33 million international)[16] - As of 3Q'25, Volaris' revenue was $2991 million and Viva's revenue was $2365 million[16] - As of 3Q'25, Volaris' EBITDAR was $990 million with a 33% margin, and Viva's EBITDAR was $873 million with a 37% margin[16] - As of 3Q'25, Volaris' net debt was $3071 million and Viva's net debt was $1883 million[16] Market Opportunity - There are 39 million Mexican-origin individuals living in the US[22] - There are 101 million national tourists in the Mexican leisure market in 2024[22] - Mexico received $41 billion in foreign direct investment in 2025[22] - Mexico had 120 million air passengers in 2024[22]

Financial Performance & Outlook - Lamb Weston's Q2 2026 net sales increased by 1% compared to Q2 2025, which includes a favorable foreign currency impact of $24 million[28, 30] - North America net sales were flat, with volume up by 8% but price/mix down by 8%[30, 31] - International net sales increased by 4%, but decreased by 1% on a constant currency basis, with volume up by 7% and price/mix down by 8%[31] - Adjusted EBITDA decreased by $9 million, while adjusted gross profit decreased by $16 million[32] - The company reaffirms its fiscal year 2026 outlook, projecting net sales between $635 billion and $655 billion, and adjusted EBITDA between $1 billion and $12 billion[47] Cash Flow & Capital Allocation - The company has approximately $83 million in cash and cash equivalents, and $135 billion available under its revolving credit facility[39] - Net cash provided by operating activities for the first half of fiscal year 2026 was approximately $530 million, with capital expenditures of $156 million[39] - Free cash flow was $375 million, and the company returned $92 million to shareholders through dividends ($52 million) and share repurchases ($40 million)[39] - The board authorized a 3% increase in the quarterly dividend[9, 46] Strategic Initiatives - The company is executing its "Focus to Win" strategy, which includes a cost savings program expected to yield $100 million in savings in fiscal year 2026 and $250 million by the end of fiscal year 2028[9, 19] - Lamb Weston is optimizing its global supply chain, including restarting curtailed production in North America to meet higher demand[9, 15]

Business Verticals & Strategic Initiatives - ProPhase Labs is pursuing near-term cash recovery of over $50 million from COVID-19 receivables through Crown Medical Collections [7, 11, 24, 26, 92] - BE-Smart, an esophageal cancer diagnostic test, targets a $7-14 billion market [8, 34] - Nebula Genomics possesses a 16-petabyte DNA dataset, equivalent to roughly 150 million ancestry SNP-based tests, spanning 130 countries [9, 62] - ProPhase Labs signed a Letter of Intent for a proposed reverse merger with Advanced Biological Laboratories S A (ABL), with ABL potentially becoming the majority owner (~76%) [20, 23] BE-Smart Esophageal Cancer Diagnostic - BE-Smart achieved greater than a 95% technical success rate in a key validation study evaluating its performance with esophageal brush cytology samples [44, 93] - The change in the annual incidence of Esophageal Adenocarcinoma (EAC) was 766 67% higher in 2017 compared to 1973 [32] Nebula Genomics - Nebula Genomics' DNA Complete offers Whole Genome Sequencing (WGS) analyzing virtually 100% of an individual's DNA [63] - DNA Expand expands raw DNA data more than 50 times to over 35 million genetic variants [73] Financial Restructuring - ProPhase Labs sold Pharmaloz Manufacturing for $23 6 million [18] - The company is saving over $6 million per year by shutting down the genomics laboratory [18]

Financial Performance - Q2 FY26 - Conagra's Q2 FY26 organic net sales decreased by 30% compared to the previous year, totaling $2975 million[51, 52, 53] - Adjusted EPS for Q2 FY26 was $045, a decrease of 357% year-over-year[51] - Adjusted operating margin for Q2 FY26 was 113%, a decrease of 406 bps compared to the previous year[51, 54, 55, 57] - For H1 FY26, organic net sales decreased by 19% to $5586 million[51, 76] - Adjusted EPS for H1 FY26 was $085, a decrease of 309% year-over-year[51] Segment Performance - Q2 FY26 - Grocery & Snacks net sales were $1209 million, with a 15% organic net sales decrease[53] - Refrigerated & Frozen net sales were $1251 million, with a 51% organic net sales decrease[53] - International net sales were $230 million, with a 29% organic net sales decrease[53] - Foodservice net sales were $288 million, with a 02% organic net sales increase[53] Key Business Trends - Frozen retail volume sales showed a return to growth on a two-year basis, with a +08% change in Q2 FY26[14, 15] - 90% of frozen products held or gained volume share vs 2 years ago[15] - Conagra's frozen single-serve meals volume share of category was 529% in Q2 FY26, a +05 percentage point change vs 2 years ago[18, 19, 20, 21] - Conagra's frozen vegetables volume % change was +91% vs 2 years ago[22, 23] - Conagra's frozen vegetables volume share of category was 191% in Q2 FY26, a +13 percentage point change vs 2 years ago[24, 25]